We are live on
!
Find out more
TG
TRV GP Portfolio holdings
AUM
$18.9M
1-Year Est. Return
541.67%
This Fund
S&P 500
This Quarter
Est. Return
+48.45%
1 Year Est. Return
+541.67%
3 Year Est. Return
+3,178.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$17.7M
(+13%)
Cap. Flow
-$29M
Cap. Flow
% of AUM
-18.28%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
1
Top Buys
No buys this quarter
Top Sells
| 1 |
CytomX Therapeutics
CTMX
|
+$29M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rhythm Pharmaceuticals
RYTM
$7.28B
| $124M | 78.39% |
3,981,437
| – | – |
|
2
KALA BIO
KALA
$15.7M
| $22.7M | 14.31% |
662
| – | – |
|
|
CARM
3
DELISTED
Carisma Therapeutics
CARM
| $9.44M | 5.95% |
242,080
| – | – |
|
4
Larimar Therapeutics
LRMR
$381M
| $2.15M | 1.36% |
17,531
| – | – |
|
|
5
CytomX Therapeutics
CTMX
$798M
| – | – |
-1,020,348
| Closed | -$29M |
|
Similar funds
KA
FRGX
DHRFI
SA
YECIP
FFIM
ES
HCMT
TRV GP's Q2 2018 Portfolio in Review
As of Q2 2018, TRV GP held 5 positions worth $159M, up 13% from $141M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
TRV GP withdrew a net $29M in Q2 2018, closing 1 position. Its most notable exit was CytomX Therapeutics, an estimated $29M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- TRV GP fully exited CytomX Therapeutics in Q2 2018, selling an estimated $29M.
- TRV GP's ten largest holdings make up 100% of its $159M portfolio in Q2 2018.
- TRV GP opened 0 new positions and closed 1 in Q2 2018.
- TRV GP's portfolio value rose 13% quarter-over-quarter to $159M.
Based on TRV GP's 13F filing for Q2 2018, filed 7 Aug 2018.